| 1001 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
65 |
| 1002 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
61 |
| 1003 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
65 |
| 1004 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
19 |
| 1005 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
65 |
| 1006 |
Apheresis |
Allogeneic
|
Mixed Phenotype Acute Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
47 |
| 1007 |
Apheresis |
Allogeneic
|
Polycythemia Vera
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
61 |
| 1008 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
56 |
| 1009 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
53 |
| 1010 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
55 |
| 1011 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome, Myeloproliferative Neoplasms
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
34 |
| 1012 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
50 |
| 1013 |
Apheresis |
Allogeneic
|
Myelodysplastic Disorders
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
71 |
| 1014 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
64 |
| 1015 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
54 |
| 1016 |
Apheresis |
Autologous
|
Non-Hodgkin lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
50 |
| 1017 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
50 |
| 1018 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
35 |
| 1019 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
54 |
| 1020 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
52 |
| 1021 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1022 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
55 |
| 1023 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1024 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1025 |
Apheresis |
Allogeneic
|
Primary myelofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
71 |
| 1026 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
47 |
| 1027 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 1028 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1029 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
44 |
| 1030 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
59 |
| 1031 |
Apheresis |
Autologous
|
Lymphoma Non-Hodgkin
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
58 |
| 1032 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Sweden
|
59 |
| 1033 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
2 |
| 1034 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
41 |
| 1035 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
France
|
48 |
| 1036 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Sweden
|
64 |
| 1037 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
63 |
| 1038 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
64 |
| 1039 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
58 |
| 1040 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome, Myeloproliferative Neoplasms
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
68 |
| 1041 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome, Myeloproliferative Neoplasms
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
59 |
| 1042 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
56 |
| 1043 |
Apheresis |
Allogeneic
|
Diffuse Large B-cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Belarus
|
53 |
| 1044 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
60 |
| 1045 |
Apheresis |
Allogeneic
|
Immunodeficiency – LRBA
|
Hematology
|
2025
|
Standard Therapy
|
Turkey
|
14 |
| 1046 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
20 |
| 1047 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
65 |
| 1048 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
54 |
| 1049 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
75 |
| 1050 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
58 |
| 1051 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
48 |
| 1052 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
37 |
| 1053 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Chile
|
40 |
| 1054 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
72 |
| 1055 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Switzerland
|
65 |
| 1056 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
68 |
| 1057 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Estonia
|
9 |
| 1058 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
63 |
| 1059 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Sweden
|
67 |
| 1060 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
45 |
| 1061 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
59 |
| 1062 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
69 |
| 1063 |
Apheresis |
Autologous
|
T-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1064 |
Apheresis |
Allogeneic
|
Acute lymphoblastic leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
42 |
| 1065 |
Apheresis |
Autologous
|
Primary central nervous system lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1066 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome/ Acute Myeloid Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1067 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
42 |
| 1068 |
Apheresis |
Autologous
|
T-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
55 |
| 1069 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
72 |
| 1070 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 1071 |
Apheresis |
Autologous
|
Central nervous system lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1072 |
Apheresis |
Autologous
|
Follicular lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
67 |
| 1073 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1074 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1075 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
64 |
| 1076 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Portugal
|
63 |
| 1077 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
67 |
| 1078 |
Apheresis |
Autologous
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1079 |
Apheresis |
Autologous
|
Hodgkin lymphoma rezidiv
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1080 |
Apheresis |
Autologous
|
Non-Hodgkin lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1081 |
Apheresis |
Autologous
|
T-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
67 |
| 1082 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1083 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1084 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1085 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 1086 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
55 |
| 1087 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
60 |
| 1088 |
Apheresis |
Allogeneic
|
Fanconi’s Anemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
6 |
| 1089 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
69 |
| 1090 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
54 |
| 1091 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Macedonia
|
56 |
| 1092 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
CROATIA
|
64 |
| 1093 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
75 |
| 1094 |
Apheresis |
Allogeneic
|
T-cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
NETHERLANDS
|
65 |
| 1095 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
65 |
| 1096 |
Apheresis |
Allogeneic
|
Myeloid Sarcoma
|
Hematology
|
2025
|
Standard Therapy
|
Brazil
|
48 |
| 1097 |
Apheresis |
Allogeneic
|
T-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
17 |
| 1098 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
13 |
| 1099 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
69 |
| 1100 |
Apheresis |
Allogeneic
|
T-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
13 |